NEW STUDY RESULTS FURTHER ENHANCES THE ROLE OF ELOXATIN® IN EARLY AND ADVANCED STAGES OF COLON CANCER
Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France – May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study findings provide additional positive data on Eloxatin® in various stages of colon cancer, either in combination with 5-fluorouracil (5-FU) plus leucovorin (LV) (5-FU/LV) or with biological agents such as